Behavioral Health Group Announces Transition of CEO Andrew Love to Advisory Role; Board Appoints Chairman, Mike Cannizzaro, as Chairman and CEO
DALLAS, TX, July 25, 2012 /PRNewswire/ — The Board of Directors of Behavioral Health Group (“BHG” or “the Company”) today announced that Andrew Love has stepped down as Chief Executive Officer and Director and has transitioned to a consulting role with the Company as he pursues a new opportunity. He is succeeded by Michael N. Cannizzaro, BHG’s Chairman.
Andy said of his transition: “It was an honor to build and lead BHG from inception to its sale a year ago to the Frontenac Company. I am delighted to continue working together with the leadership team of professionals at BHG and Frontenac, and I am grateful for the support I’ve received from the Board of Directors and our team members over the last six years as we have built BHG into a leader in the field of opioid addiction treatment.”
Mr. Love added, “BHG’s growth will undoubtedly accelerate under the outstanding and experienced leadership of Mike Cannizzaro, with whom I have enjoyed working over the last year. I look forward to my continued support of BHG as a co-founder, advisor, and shareholder.”
BHG’s Chairman and CEO, Mike Cannizzaro, said: “The Board expresses its gratitude to Andy for his dedicated service to BHG since co-founding the company in 2006, and we thank him for the vision and leadership he brought to the company. We are delighted that we will be able to draw on Andy’s talents and experience through his participation as an advisor to the Company. We wish him every success in his future endeavors.”
Mike Cannizzaro, Chairman and CEO, has 36 years of leadership experience in healthcare companies, including Baxter Healthcare, Caremark International, Beltone Electronics, National Nephrology, and Sunrise Medical, to name a few. He was also an operating partner of JW Childs Associates, a leading private equity firm based in Boston.
About Behavioral Health Group
Behavioral Health Group (BHG) is a leading provider of opioid addiction treatment services. BHG utilizes pharmacotherapy (maintenance and detoxification) and behavioral therapy (counseling) to treat both the bio-chemical and psycho-social aspects of addiction. In doing so, BHG offers its patients their best shot at successful recovery. With 23 outpatient treatment centers across the midwest/south/southeast, BHG provides a critical service to thousands of individuals and their communities across the country. BHG’s treatment centers are accredited by The Joint Commission.
For more information, call (214) 365-6100, email firstname.lastname@example.org, or visit https://bhgrecovery.com.
Behavioral Health Group Contact: James F. Draudt